The mechanistic role of colonic low folate metabolic stress (LFMS) in colorectal cancer (CRC) malignancy development remains unknown. Folate analysis on the 99 paired human CRC tissues localized LFMS to the deep invasive T3/T4 staged tumours with hypo-methylated sonic hedgehog (Shh) promoter region and amplified expressions of Shh ligand and Gli1 effector, which coincided with deregulated expressions of the epithelial-mesenchymal transition (EMT) mediators. Colonic folate levels of CRC were inversely correlated with pluripotent expressions of the SOX2, NANOG and OCT4 markers (p < 0.05). Exposure of human colon adenocarcinoma cells to LFMS microenvironment significantly hypomethylated Shh promoter region, activated Shh signaling, induced transcript and protein expressions of the pluripotent markers, promoted trans-differentiation as EMT by deregulation of Snail mediator and epithelial marker E-cadherin, increased MMP2/MMP9 enzymatic digestion on matrix protein for invasion, and promoted self-renewal capability of anchorage-independent tumor-spheroid formation. LFMS-induced cancer stem cell (CSC) signature and CRC invasion is synergized with inhibition of DNA methylation by 5-Aza-2-deoxycytidine (5AZA) in rewiring EMT genotypes, which can be blockade by the Shh inhibitor (cyclopamine). The in vivo and in vitro data corroboratively identify CSC-like molecular targets specific to the LFMS-predisposed invasive CRC through reprogramming DNA methylation-activated Shh signaling. The study highlights CSC targets specific to LFMS-predisposed invasive CRC in optimizing folate co-chemotherapy to minimize tumour metastasis potential of CRC patients.
The mechanistic role of colonic low folate metabolic stress (LFMS) in colorectal cancer (CRC) malignancy development remains unknown. Folate analysis on the 99 paired human CRC tissues localized LFMS to the deep invasive T3/T4 staged tumours with hypo-methylated sonic hedgehog (Shh) promoter region and amplified expressions of Shh ligand and Gli1 effector, which coincided with deregulated expressions of the epithelial-mesenchymal transition (EMT) mediators. Colonic folate levels of CRC were inversely correlated with pluripotent expressions of the SOX2, NANOG and OCT4 markers (p < 0.05). Exposure of human colon adenocarcinoma cells to LFMS microenvironment significantly hypomethylated Shh promoter region, activated Shh signaling, induced transcript and protein expressions of the pluripotent markers, promoted trans-differentiation as EMT by deregulation of Snail mediator and epithelial marker E-cadherin, increased MMP2/MMP9 enzymatic digestion on matrix protein for invasion, and promoted self-renewal capability of anchorage-independent tumor-spheroid formation. LFMS-induced cancer stem cell (CSC) signature and CRC invasion is synergized with inhibition of DNA methylation by 5-Aza-2-deoxycytidine (5AZA) in rewiring EMT genotypes, which can be blockade by the Shh inhibitor (cyclopamine). The in vivo and in vitro data corroboratively identify CSC-like molecular targets specific to the LFMS-predisposed invasive CRC through reprogramming DNA methylation-activated Shh signaling. The study highlights CSC targets specific to LFMS-predisposed invasive CRC in optimizing folate co-chemotherapy to minimize tumour metastasis potential of CRC patients.
Colorectal cancer (CRC) is one of the most lethal malignancies worldwide. The 5-year survival rate of patients with metastatic CRC is <5%. 1 Recent advances have proposed the malignancy CRC are the cancer stem cell (CSC) disease. 2 Malignant cancers in the tumor bulk may originate from a small fraction of CSCs signified by the self-renewal property, trans-differentiation, and expressed pluripotency markers (SOX2, OCT4, and NANOG) to acquire invasive and metastatic capacity. 3 The trans-differentiation of CSCs is exemplified by multistage epithelial-mesenchymal transition (EMT) through the mediator expression of Snail to downregulate E-cadherin, an epithelial cell marker, which can cause CSCs to lose their epithelial junction and begin to migrate. 4 Mesenchymal CSCs express matrix metalloproteinase (MMP) to digest the matrix protein for invasion. CSCs acquire selfrenewal propensity to form anchorage-independent tumorsphere for distant organ attachment. 5 Induction of EMT and oncospheroid formation of human CRCs enhanced in vitro invasion and in vivo metastasis. 6 The developmental embryonic stem cell pathway, sonic hedgehog (Shh) signaling, is essential for CSC fate determination of certain cancers. 7 Human colon cancer cells harbor activated Hh signaling, transduced by the SHH ligand and Gli1 effector; the signaling is critical for expressing stemness signatures of SOX2, OCT4, and NANOG, 8 EMT differentiation and tumor metastasis. 9, 10 Blockage of SHH signaling by pathway inhibitor cyclopamine (CYC) reduces the expression of CSC gene signatures of OCT4 and NANOG in human colon cancer-derived oncospheres. 11 Coexpression of OCT4 and NANOG induced CSC-like properties, EMT transdifferentiation, and cancer malignancy progression.
12 SOX2 expressions deregulated EMT and correlated with liver and lymph node metastasis in right sided colon cancer. 13, 14 Accumulating evidence suggest that Shh-activated expression of the pluripotent signatures involves in CRC malignancy transformation, yet the molecular etiology and microenvironmental factors to provoke CSC-associated Shh signaling remains obscure.
Folate is an essential B vitamin involving in one-carbon metabolism critical to DNA methylation and synthesis. Folate deprivation results in intracellular low folate metabolic stress (LFMS) signified by DNA hypomethylation and chromosome instability, which is well documented as the mutagenic factors that promote colonic carcinogenesis. [15] [16] [17] Due to dietary insufficiency, genetic polymorphisms of one-carbon enzymes, clinical complications or/and antifolate chemotherapy, CRC patients frequently suffer from poor blood folate status which creates LFMS microenvironment for the host, preexisting neoplastic or/and cancer cells. 18 Target pathological time window which colonic folate modified malignancy CRC development is unknown. 19, 20 There is as yet no evidence in colonic LFMS that may reprogram CSC-like signatures to influence CRC malignancy. The hypothesis was tested using the in vivo human CRC tissue pairs and in vitro human colonic adenocarcinoma cancer models. The working mechanisms by DNA-methylation activated SHH signaling to mediate CSC-like features and CRC invasion are explored.
Materials and Methods

Collection of the paired human CRC tissues
Between 2008 and 2012, patients diagnosed as having CRC were recruited from the gastrointestinal department of ChiMei Hospital, Tainan, Taiwan. The inclusion criteria for the study were as follows: (1) histopathological diagnosis of CRC lesions, (2) matched tumor and adjacent nontumor paired specimens, and (3) no chemotherapy or radiotherapy administered before surgery. The pathological stages of CRC were classified by physicians and pathologists according to the recognized criteria of the tumor, regional lymph node, and metastases system based on the AJCC/UICC publication. 21 Ninety nine tumor-normal pairs matched using standard methods were collected, immediately frozen in liquid nitrogen, and stored in the Chi-Mei Tumour Bank for further biochemical and molecular analyses. The Joint Ethical Committee of Fu-Jen University and Chi-Mei Hospital approved the study, and all patients provided informed written consent before tumor resection.
In vitro human colon cancer cells
The SW480 human colon adenocarcinoma cell line obtained from the National Development Center of Biotechnology (Taipei, Taiwan) was short tandem repeat profiled as the authentic CRC cell line. SW480 cells were maintained as a monolayer culture in a control medium (RPMI1640) supplemented with 2.0 g/L of sodium bicarbonate, 10% (v/v) fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 mg/mL of streptomycin at 378C in a humidified 5% CO 2 incubator. Folate-deprived cells were cultured in folate-deficient (FD) RPMI 1640 medium, with the same supplements as those in the control medium.
Spheroid formation assay
Oncosphere formation was induced by seeding the control and FD cells at a cell density of 1,000 cells/mL in suspension tumorsphere medium composed of serum-free Dulbecco modified Eagle medium supplemented with 2% B27 (Life Technologies, Invitrogen TM ) plus 20 ng/mL human recombinant epidermal growth factor, 10 ng/mL human recombinant basic fibroblast growth factor, 100 IU/mL penicillin, and 100 lg/mL streptomycin. The spheres (tight, spherical, nonadherent masses > 40 lm in diameter) in each well were photographed and counted under a phase-contrast microscope at 403 magnification.
Transwell invasion and gelatin zymography assay
Cellular invasion was examined using a modified Millicell culture insert as previously described. 22 MMP-2 and -9 activities in the serum-free media were determined through gelatin zymography assay as previously described.
22
RNA extraction and real-time reverse transcription polymerase chain reaction
The total RNA was extracted using an RNAzol Bee-RNA isolation kit. Gene transcripts were amplified with specific primers (Supporting Information Table 1 ). The protocol is previously described elsewhere.
What's new? Lack of folate causes oxidative stress in cells, and this stress spurs carcinogenesis. But few studies have shown how folate deficiency changes colon cells to induce cancer. These authors tested 99 paired colon cancer and non-cancer tissue samples to uncover the effect of low folate metabolic stress (LFMS). They observed that higher stage, more invasive tumors had depleted folate compared with non-CRC counterpart samples. They also showed that LFMS reduced methylation of Shh promoter region, activating the Shh pathway, which boosted cells' ability to proliferate and spread.
Western blotting
Total proteins were extracted, and Western blotting was performed according to previous protocols. 22 Methylation status of the SHH promoter Genomic DNA was isolated using the standard protocol. Bisulfite modification of the genomic DNA was performed using the EpiTect PCR Control DNA set (Qiagen, Hilden, Germany), as previously described. 23 M and U primers were selected to detect methylated and unmethylated DNA sequences, respectively (Supporting Information Table 1 ).
The conditions for methylation-specific polymerase chain reaction (PCR) (MSP) were previously described. 22 Pyrosequencing was performed on PCR-amplified products by using M and U primers.
Folate assay
Folate content in cells and tissues was quantified using a microbiological assay by using glycerol-protected Lactobacillus casei (ATCC no. 7469) in 96-well microtitre plates as previously described elsewhere. 22 
Statistical analysis
Statistical analyses were performed using a statistical analysis system (SAS/STAT version 6.12, SAS Institute, Cary, NC, USA). The continuous variables were compared using oneway analysis of covariance, followed by Scheffe's test and the least significant difference test. Differences in discontinuous variables were evaluated using chi-squared and Fisher's exact tests. Dependence between variables was evaluated using Pearson's correlation coefficients.
Results
Colonic folate and CSC signaling markers as a function of CRC pathological courses
The 99 paired human CRC had mean colonic folate at the levels of 28 6 22 for tumors and 20 6 10 ng/g protein for paired non-tumour tissue (Supporting Information Table 2 ). Despite no statistical significant difference, a 30% elevated CRC folate with 2-fold wider variation compared with the non-CRC folate was observed. As colonic folate of the paired human CRC was stratified by pathologic and malignancy courses, LFMS were specifically localized at the T4-staged tumours with 30% drop of colonic folate compared with the T3-staged tumours (p < 0.05) ( Fig. 1a and Supporting Information Table 2 ). Depleted folate levels of the paired non-CRC tissues were localized at the perineural invasive stage compared with their less aggressive counterparts and were associated with elevated CEA tumour markers (м5 ng/mL) (p < 0.05). At such invasive stages, CRC folate levels were 30% higher than their paired non-CRC folate (p < 0.05). As 50% intracellular folate depletion resulted in elevated oxidative and genomic damage, 22 folate levels less than mean folate value of the non-CRC paired tissues were used as the cutout point to define LFMS. High frequency of LFMS-embedded CRC was co-localized with tumours at the T3/T4/N0/M0 stage (Fig. 1a) . Colonic folate status of the paired CRC tissues did not differ with respect to tumour size, numbers, age, sex, and genetic polymorphisms (MTHFR C677T locus and TS 5 0 -untranslated region 3 R/3 R locus) (Supporting Information Table 2 ). When the subset of paired CRC tissues at the T2-T4 stages was selected for DNA methylation analysis, the invasive CRC tissues carried a demethylated SHH promoter, as revealed by increased PCR product intensity through U primer amplification (Fig. 1b) . The paired non-CRC tissues showed a mixed methylation status of the SHH promoter (Fig. 1b) . Quantitative analysis through pyrosequencing revealed the significantly demethylated status of the SHH promoter in the CRC versus non-CRC tissues (Fig 1b) . Amplified expressions of SHH transcripts were coined on the CRC tissues compared with the paired non-CRC tissues along the malignancy stages (Supporting Information Table  3 ). CRC tissues at the T4/Perineural invasive stages showed highly overexpressed SHH transcripts by 27 to 58-fold as compared with the less invasive stages (Fig. 1c) . CRC expression of the Gli1 effector, target of activated Shh signaling, was correspondingly amplified by > 3-fold increase on T2/ T4/M0-staged tumors ( Fig. 1d and Supporting Information Table 4 ). Expressions of HHIP, a SHH signaling repressor, were down regulated ( Fig. 1d and Supporting Information Table 5 ) as well as the EMT markers of E-CADHERIN and BETA-CATENIN in the CRC tissues ( Fig. 1d and Supporting Information Tables 6 and 7) .
Association of expressed pluripotent markers with colonic folate in the paired invasive-staged CRC As compared with the paired controls, the CRC's pluripotent markers (SOX2, OCT4 and NANOG) at any TNM stage were increased by 0.1-2.3 fold with the highest magnitude on the NANOG marker ( Fig. 2a and Supporting Information Tables  8-10 ). Expressions of three pluripotent markers peaked at the T3/T4/N0/M0 stages. Pearson's correlation analysis revealed that expressions of SOX2, NANOG and OCT4 among the specific staged-CRC tissues were significantly and inversely associated with tumor folate levels (Figs. 2b-2d) . The significance of the data did not survive if the obvious single outliner in each CRC parameter was removed. It should be noted that the single outlier of folate-CSC marker was specific to both the CRC and paired non-CRC counterpart (Figs. 2b-2d ), yet the paired non-CRC tissues did not show such folate-CSC markers correlation (Figs. 2b-2d) . The data suggest that this single outlier may represent for a rare, yet truly manifested clinical condition for the particular patient case, which should stay for the analysis. Tumour folate did not correlate with Shh expressions (data not shown), yet was positively associated with serum CEA tumour marker (r 5 0.343, p 5 0.001).
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In vitro folate deprivation (FD) promoted DNAhypomethylation activation of SHH signaling in human colon adenocarcinoma cells
To investigate the causal effect of LFMS to promote Shhmediated CSC potential and invasion, the SW480 cell line was selected based on its' close resemble to the human primary and non-metastasis tumour as the differentiated colon adenocarcinoma with p53 mutation. Cultivation of the SW480 cells in FD microenvironment for 24-72 hrs resulted in intracellular folate depletion by 50% (Fig. 3a) , which folate levels were well documented to result in increased genotoxic stress denoted as LFMS. 22 Compared with the controls, FD-exposed SW480 cells exhibited hypomethylated status of the SHH promoter (Fig. 3b) , which was further demethylation by DNA methyltransferase I inhibitor 5-AZA, evident by increased intensity of PCR product by U primer (Fig. 3b) . Demethylated Shh promoter of FDexposed SW480 cells coincided increased expressions of SHH transcripts ( Fig. 3c ) and ligand protein (Fig. 3d ) by 1.5-fold, which were additionally amplified by 0.5-1 fold upon the 5-AZA treatment and were abrogated by Shh inhibitor CYC (Figs. 3c  and 3d ). Correspondingly, increased transcript expressions of the Gli1 effector (Fig. 3e) and Patch receptor (Fig. 3f) , both of which are SHH signaling targets, was evidenced in the FD-exposed, 5-AZA-treated, and 5-AZA 1 FD-exposed cells. Blockage of Shh signaling pathway by CYC abolished the activation of SHH-GLI1 signaling in the 5-AZA 1 FD-treated cells (Figs. 3b-3f ).
Shh signaling mediated and DNA methylation-modified FD-activated cancer stem cell-like signatures
As shown in Figure 4 , FD-exposed SW480 cells developed CSC-like feature as EMT trans-differentiation by inducing transcript expressions of SNAIL (Fig. 4a) and down regulation of BETA-CATANIN (Fig. 4c ) and E-CADHERIN, the epithelial markers (Figs. 4b) . Suppression of target gene of SNAIL transcription factor, MMP2, was relieved and FD promoted transcript and protein expressions of MMP2 (Figs. 4d  and 4e ). The proteolytic activities of MMP-2 and -9 enzymes were correspondingly promoted by FD exposure (Fig. 4e) . Pretreatment of FD-exposed cells with 5-AZA augmented EMT markers by 3-fold increases of SNAIL and MMP2 expression and 2.5-fold increases of MMP-2 activity (Fige. 4a-4e). CYC treatment abolished the FD-and 5-AZAinduced expression of SNAIL, E-CADHERIN, MMP2, and MMP9 at the transcript expression and activity levels (Figs. 4a-4e). The FD-induced CSC potential was further signified by increased transcript expressions of the pluripotent markers OCT4, SOX2 and NANOG, which were abolished by CYC treatment on OCT4 and SOX2 (Fig. 4f) . Treatment of FDexposed cells with 5-AZA did not modulate expressions of these CSC markers. Activation on protein expressions of the pluripotent markers was observed for FD-exposed cells, whereas 5-AZA and CYC treatment abolished the FD-induced CSC markers (Fig.  4g ).
Shh signaling mediated and DNA methylation-modified FDenhanced invasion and self-renewal ability of anchorageindependent oncospheroid formation As shown in Figure 5a FD significantly promoted invasion of SW480 cells by 4-fold, which was synergized with the 5-AZA treatment by 7-fold increases. CYC treatment abolished the 
FD-and 5-AZA-enhanced invasion of SW480 cells. In the absence of FD exposure, the 5-AZA treatment moderately enhanced cell invasion, which was unaffected by CYC. Blockade of inflammatory nuclear factor-jB signaling by Bay inhibitor did not modulate the invasion of the control or FD cells. When SW480 cells were anchorage-independently cultivated with the oncogenic medium, FD-exposed cells manifested the self-renewal capability, an index of CSC features, to grow into numerous large tumor spheroids during Day 8 and 14 days' oncosphere cultivation (Fig. 5b) . Additional massive nascent tumorspheres with various sizes were visualized on Day 14 of oncosphere cultivation of FD-exoised cells (Fig. 5b) . CYC treatment abolished FD-induced onco-spheroid formations. Pretreatment of FD cells with 5-AZA alone or in combination with CYC completely diminished the number and size of tumorsphere formations.
Discussion
Few prior studies using human tissue specimens have demonstrated a colonic neoplastic folate depletion, 24, 25 which was associated with increased risks for the benign adenoma. 26 It has not been exploited as to the role of colonic folate in malignancy CRC development. Our data, for the first time, localized tumour folate depletion to the T4 malignancy stage when CRCs execute deep invasion from the muscularis propria into pericolorectal tissues, penetrating to the surface of the visceral peritoneum and adherent to other organs before lymphocyte and distant organ metastases proceed. 21 High frequency of LFMSembedded CRC was specifically confined to the T3/T4/N0/M0 stage, consistent with the null association of RBC folate with local/regional metastasis of CRC. 27 Such invasive stage-specific folate depletion may be distinctive with developing tumour malignancy course, which was independent of CRC risk factors such as sex, age, and one-carbon genetic polymorphisms at MTHFR C677T locus and TS 5'UTR 3 R locus. 23 In relative to the paired non-CRC counterpart, differentially elevated changes of tumour folate, however, were coined for highly proliferated CRC with increased CEA tumour markers, at the perineural invasive stage, and high alcoholic intake. Given the positive association of tumour folate with tumour CEA markers, our findings add additional human evidence in support of the hypothesis that fast growing tumours demand high folate to support their proliferation and high folate dose may promote higher tumour load observed in Apc(Min/1) mice models. 28 It stands to reason that the highly proliferated CRCs may receive folate from their surroundings, competing folate acquirement with their paired non-CRC tissues. Indeed, colonic folate depletion of the paired-non-CRC tissues as to elevated folate-CRC at the above designated stage was detected compared with their less aggressive counterparts. Such differential and pronounces . M: methylated DNA primer to amplify the 127-bp PCR product. U: unmethylated DNA primers to amplify the 131-bp PCR product. Normal human DNA (Control U) and in vitro methylated DNA (Control M) were used as negative and positive controls for methylation, respectively. Expressions of SHH transcript (c) and protein (d), and its target gene of the GLI1 effector (e), PTCH1 receptor (f), were analyzed. Values in the control and FD groups without a common letter differ at p < 0.05. *compared with the control and FD group by using the Student's t test at p < 0.05.
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variation of CRC folate changes along the specific CRC pathological courses was further confirmed by 2-fold wider variation deviation than non-CRC folate variation, which is consistent with the previously observed wide range of adenomatous folate levels. 26 Regardless it is a causal or consequence effect, the findings suggest the considerable biological variability of folate depletion or accumulation, possibly corresponding to the distinctive folate demand nature to the differential malignancy developing purposes of the heterogeneous tumours. Our data thus inform the dual time windows of CRC folate imbalance either at the invasion stages of folate depletion or at the proliferated phase of competitive folate increment through microenvironment folate redistribution. The dose-and stage-specific effect of colonic tumour folate is in line with the dual roles of folate intakes on CRC risks as proposed by the observational and clinical studies. [18] [19] [20] 29 The precise mechanisms underlying the FD-reactivated Shh signaling to induce CSC potentials remain elusive. Aberrant site-specific CpG island methylation on the SHH promoter region was proposed as a putative regulation of signal activation. 33 A hypomethylated SHH promoter has been correlated with increased transcript expression in primary CRCs, 34 in microsatellite and chromosomal stable colon cancers, 35 and in invasive CRC cells. 22 Our data demonstrate that FD induced the hypomethylated promoter region of the SHH ligand, which coincided with its increased transcript and protein expression, and activated pathway signaling by elevated transcriptional factor Gli1 expression. Treatment of FD-SW480 cells with DNMT1 inhibitor (5-AZA) enforced the demethylation of the SHH promoter, synergized the FD-activated SHH signaling pathway, and potentiated FD-induced EMT and invasiveness, which was abolished by Shh signaling inhibitor CYC. The data suggested that FD-reactivated Shh signaling to induce CSC potentials and metastasis potentials was epigenetically modulated, which mechanistic pathways were depicted in Figure 5c .
Such LFMS-mediated epigenetic regulation on CSC potentials may not be limited to DNA methylation-activation of Shh signaling. Direct DNA-methylation reprogramming of the promoter DNA methylation of the pluripotent stemness markers has been considered one of the prerequisite to maintain the self-renewal and multi-potency of CSCs. 36 Epigenetic arrays in pancreatic CSCs revealed demethylated promoter regions of pluripotent stemness genes in the SOX9, NANOG and OCT4 transcriptional network. 37 In human germ cell development, the CpG islands of the NANOG promoter are hypermethylated to suppress pluripotency expression to prevent from malignancy transformation. 38 Despite a reduced in vivo and in vitro CRC folate was strongly associated with increased expressions of the pluripotent NANOG markers (Fig. 2) , inhibition of DNA methylation by 5-AZA did not modulate the LFMS-induced NANOG expressions, suggesting an independent effect of DNA methylation in LFMSpromoted CSC-like pluripotent markers. 5-AZA works as the DNA methyltransferase 1 (DNMT) inhibitor. It has been reported that expression of DNMT is elevated during the progression stages of colon cancer.
39 DNMT1-knockout HCT116 cells have fewer stem cell markers and CSCs with decreased tumor formation following xenotransplantation. 40 Mammary gland-specific DNMT1 deletion protects mice from mammary tumorigenesis by limiting the CSC pool. 41 Given the fact that the hepatic transcript and protein expressions of DNMT1 were elevated in folate-and methyldeficient rats, 42 it is likely that FD promotes DNMT1 activity of colon cancer cells to mediate oncosphere formation, which can be abolished by DNMT1 inhibitor (5-AZA) treatment. Indeed, our data showed that 5-AZA treatment partly reversed FD-induced anchorage-independent oncospheroid formation. It begs one of the reasons for the differential influence of DNMT1 inhibitor as 5-AZA on LFMS-induced CSCs' self renewal capability, LFMS-promoted invasion and EMT of CSC features. The dual role of the DNMT1 inhibitory impact on FD-reprogrammed CSC potentials and invasion warrants studies.
The present study embraced several limitations. The most important one is the small sample size of human paired CRC tissues with reduced statistical power for subgroup analysis. Tumor specimens were limited amounts for immunoblotting assays on pluripotent CSC markers. Genetic expression data in any tissue other than embryonic tissues are not the direct evidence to prove truly expressed pluripotent markers, which warrants studies to confirm folate-CSC signatures correlation. Despite our in vitro data robustly indicate that LFMS promoted CSC potential to mediate colon cancer invasion, prospectively designed studies analyzing these related factors both in precancerous lesions and invasive tumor species are warranted.
In summary, our in vitro and in vivo data identify the critical CRC malignancy developing time window at the deep tissue invasive stage when LFMS hijacks CRC to epigenetically reprogram Shh-activated cancer stem cell signatures. The study highlights the CSC-like molecular targets and the specified malignancy stages when folate cotherapeutic program can be optimized to minimize CRC metastasis incidence in developing personalized nutritional medicine intervention.
